Brand profile · Biotechnology Research

CSL

Melbourne, Victoria-based CSL operates in Biotechnology Research. It is publicly held, and its site is csl.com. It holds two addresses on record across two office countries. Headcount on record is 23,318. Its work is tagged vaccines and biotechnology. Its latest round on record is Post IPO equity, US$111.0M.

csl.com LinkedIn

Profile live Public Company 2 office countries US$ 111.0M Post IPO equity
Counted staff
23,318
self-reported 10,001–100,000 band
Founded
Not recorded
Legal entities
None matched
Office countries
2
2 addresses
Funding rounds
1
Post IPO equity · Mar 2004 · US$ 111.0M
Company type
Public Company
self-reported
Use this profile Compare Your shortlist

Description

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies.

Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.

See our community guidelines: https://bit.ly/3Bs17Ra

Specialties

All 5 specialties
  • biopharma
  • Complex biologicals
  • vaccines
  • plasma and plasma derived therapeutics
  • biotechnology

Locations

2
Countries with an office address2 addresses on record
AustraliaprimaryUnited States

Country footprint

Offices in 2 countriesCountry footprint: 2 countries, primary AU. Codes: AU, US.2 countriesprimary AUAUUS
Show as table
Countries2
Primary countryAU

All codes: AU US

Addresses

  • AU655 Elizabeth St; Melbourne, Victoria 3000Primary
  • US1020 1st Ave; King of Prussia, PA 19406

Grid intelligence Members

Funding

Last round · 6 March 2004US$ 111.0MPost IPO equity
Rounds1
Round typePost IPO equity · secondary transaction
Amount (USD)111,000,000
Stage rank6
Investors named0
Since last round21 yr 10 mo

Funding

1 funding roundFunding timeline. Latest round 6 Mar 2004: Post IPO equity, US$ 111.0M.20042026Post IPO equityUS$ 111.0M1 round
Show as table
Rounds1
Axis2004 to 2026
Post IPO equity · 6 Mar 2004US$ 111.0M

Dated rounds only. The axis ends at the date this profile was last observed, not at today.

Spending power

TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.

Spending power

Notify me about spending power

Signals & hiring

Hiring, headcount and registry-change signals, streamed to members.

Latest signal
Hiring activity
Headcount trend
Notify me about signals

Financials

Registry-filed capital and financial indicators, standardised by TheGrid.

Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss
Notify me about financials

People & contacts

4 employee profiles on record · names withheld.

Names are withheld until a consented source exists.

Notify me about contacts Tell us who you need to reach and we will tell you when a consented source is live.

FAQ

How many people work at CSL?

23,318 counted staff profiles at January 2026, inside the self-reported 10001+ band.

Where does CSL have offices?

Two addresses on record across 2 countries. Primary: 655 Elizabeth St, Melbourne, Victoria 3000.

Has CSL raised funding?

One round. Latest 6 March 2004: post IPO equity, US$111,000,000.

What does CSL list as its specialties?

Five tags on the brand's own list, among them vaccines and biotechnology.

Which companies are listed alongside CSL?

189 profiles list CSL as a peer — 99th percentile in Biotechnology Research. It lists ten peers of its own.

What is CSL's website?

csl.com